MRNA vs REGN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
REGN Captures Institutional Edge (3โ1 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus REGN at 14.8x Forward P/E and 30.4% operating margin (+36.3% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against REGN sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MRNA Revenue | REGN Revenue | MRNA Op. Margin | REGN Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $140M | $5.15B | -306.0% | 49.3% | REGN |
| FY2019 | $60M | $6.56B | -906.8% | 33.7% | REGN |
| FY2020 | $800M | $8.50B | -95.0% | 42.1% | REGN |
| FY2021 | $18.5B | $16.1B | 72.0% | 55.7% | MRNA |
| FY2022 | $19.3B | $12.2B | 48.9% | 38.9% | MRNA |
| FY2023 | $6.85B | $13.1B | -61.9% | 30.9% | REGN |
| FY2024 | $3.24B | $14.2B | -121.9% | 28.1% | REGN |
| FY2025 | $1.94B | $14.3B | -158.1% | 24.9% | REGN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MRNA | REGN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $80.7B | $95.5B | Larger Scale | REGN |
| Trailing P/E Ratio Valuation | 23.0x | 20.4x | Lower Multiple | REGN |
| Forward P/E Ratio Valuation | 23.0x | 14.8x | Lower Multiple | REGN |
| Revenue Growth (YoY) Growth | +29.2% | +36.3% | Higher Growth | REGN |
| Operating Margin (TTM) Profitability | -80.8% | 30.4% | Higher Margin | REGN |
| Net Profit Margin Profitability | -110.5% | 28.5% | Higher Margin | REGN |
| Return on Equity (ROE) Capital Efficiency | -34.5% | 14.9% | Higher ROE | REGN |
| 52-Week Range Position Momentum | 67% ($22โ$281) | 82% ($592โ$992) | Stronger Trend | REGN |
| Beta / 30D Volatility Risk Regime | 2.23ฮฒ ยท 78% Vol | 0.30ฮฒ ยท 55% Vol | Lower Realized Risk | REGN |
| Unified Institutional Score Composite Signal | 40.3 / 100 (SELL) | 46.0 / 100 (HOLD) | Higher Composite | REGN |